What this test measures
CA 19-9 (carbohydrate antigen 19-9, also called sialyl-Lewis-a) is a glycoprotein found on the surface of pancreatic, biliary, gastric and colorectal cancer cells, and shed into the bloodstream. The test measures CA 19-9 in serum by immunoassay (chemiluminescence).
It is elevated in 70–90% of pancreatic adenocarcinomas, particularly advanced disease. However, it is also raised in many benign conditions — cholangitis, cholestasis from gallstones, hepatitis, pancreatitis, cirrhosis, diabetes — and in other cancers (cholangiocarcinoma, colorectal, gastric, ovarian). About 5–10% of people are Lewis-antigen-negative and cannot produce CA 19-9 even with cancer — leading to false-negative results.
Why it matters
CA 19-9's clinically useful roles are narrow but real:
• Monitoring response to treatment in confirmed pancreatic cancer • Detecting recurrence after curative-intent surgery • Supporting (not establishing) the diagnosis of pancreatic cancer alongside imaging • In cholangiocarcinoma, similar uses
It is explicitly NOT recommended as a screening test for asymptomatic individuals — NCCN, ASCO, and major guidelines all advise against this. False positives from benign biliary disease are common in India where gallstone disease is widespread, leading to anxiety, repeated imaging, and even unnecessary invasive procedures. Sensitivity for early pancreatic cancer is too low for screening.
How to prepare
No fasting required. A standard venous blood sample. Mention any liver / pancreatic / biliary disease, jaundice, recent ERCP or biliary stenting, recent cholecystitis, diabetes, smoking, and any known cancer. Stop high-dose biotin supplements 72 hours before testing if possible.
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| CA 19-9 (U/mL)[1][2][3] | < 37 U/mL (lab-specific) | Low / normal CA 19-9 in a patient with pancreatic cancer is reassuring but does not exclude disease — 5–10% of patients are Lewis-antigen-negative and never produce CA 19-9. | 37–100 U/mL: nonspecific elevation — gallstone disease, cholangitis, pancreatitis, cholestasis, diabetes. 100–1,000 U/mL: concerning for pancreatic / biliary cancer in the right clinical setting. > 1,000 U/mL: strongly suggests advanced pancreatic or biliary cancer; rarely from benign causes. |
CA 19-9 — appropriate vs inappropriate use
| Context | Appropriate use? | Notes |
|---|---|---|
| Screening asymptomatic adults | No | High false-positive rate from gallstones, cholestasis |
| Workup of suspected pancreatic mass | Adjunct | Imaging + biopsy are primary; CA 19-9 supports |
| Monitoring known pancreatic cancer | Yes | Track response; trends matter more than absolute number |
| Post-surgery recurrence surveillance | Yes | Usually every 3–6 months for 2 years, then annual |
| Workup of jaundice | Adjunct | Distinguishing malignant from benign biliary obstruction |
Frequently asked questions
Can a CA 19-9 test screen me for pancreatic cancer?
No. CA 19-9 is not recommended for screening asymptomatic adults — its false-positive rate (from gallstones, cholestasis, pancreatitis) is too high, and early-stage pancreatic cancer often does not raise CA 19-9 enough to detect. No major guideline endorses CA 19-9 screening.
My CA 19-9 is mildly elevated and my doctor found gallstones — what does that mean?
Cholestasis from gallstones commonly raises CA 19-9 modestly (often 50–500 U/mL). After the gallstones are treated and the cholestasis resolves, CA 19-9 usually returns to normal within weeks. Persistent elevation after treatment warrants further imaging.
When is CA 19-9 truly useful?
In monitoring known pancreatic or biliary cancer — tracking response to chemotherapy, detecting recurrence after surgery, and supporting (not establishing) the diagnosis alongside imaging and biopsy.
Why does some pancreatic cancer not raise CA 19-9?
About 5–10% of people are Lewis-antigen-negative (genetically) and physically cannot produce CA 19-9 — even with extensive cancer. In these patients, CEA or other markers may be tracked instead.
Do I need to fast?
No fasting is required.
How long does the report take?
Most NABL labs deliver CA 19-9 results in 24–48 hours.
Does smoking affect CA 19-9?
Smoking can raise CA 19-9 modestly. Mention smoking history when interpreting results.
Related Oncology / Tumor Markers tests
Tests commonly ordered alongside CA 19.9, or that help interpret an unexpected result.
Sources & references
- NCCN — Pancreatic Adenocarcinoma Guidelines · accessed 2026-05-30T00:00:00.000Z
- American Cancer Society — Pancreatic Cancer Tests · accessed 2026-05-30T00:00:00.000Z
- NCBI StatPearls — CA 19-9 · accessed 2026-05-30T00:00:00.000Z
- ASCO — Tumor Markers in Gastrointestinal Cancers · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your CA 19.9 test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book CA 19.9 now